Point72 Europe’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Point72 Europe’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$12.5K	Buy	+3,572	New	+$12.2K	﹤0.01%	515

Other funds holding STLN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Point72 Europe's STLN Position: Q3 2025 in Review

Point72 Europe opened a new position in Starling Oncology Institute, Inc. Common Stock (STLN) in Q3 2025: 3,572 shares worth $12.5K. The stake represents ﹤0.01% of the portfolio and ranks #515 among its holdings.

108 funds tracked by Wall St. Rank hold STLN as of Q3 2025.

Point72 Europe held 3,572 shares of Starling Oncology Institute, Inc. Common Stock worth $12.5K as of Q3 2025.
Starling Oncology Institute, Inc. Common Stock was a new Point72 Europe position in Q3 2025.
Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #515 holding.
108 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.